Literature DB >> 26647424

A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism.

Josep M Cruzado1, Pablo Moreno2, José V Torregrosa3, Omar Taco4, Richard Mast5, Carmen Gómez-Vaquero6, Carolina Polo4, Ignacio Revuelta3, José Francos2, Joan Torras4, Arantxa García-Barrasa2, Oriol Bestard4, Josep M Grinyó4.   

Abstract

Tertiary hyperparathyroidism is a common cause of hypercalcemia after kidney transplant. We designed this 12-month, prospective, multicenter, open-label, randomized study to evaluate whether subtotal parathyroidectomy is more effective than cinacalcet for controlling hypercalcemia caused by persistent hyperparathyroidism after kidney transplant. Kidney allograft recipients with hypercalcemia and elevated intact parathyroid hormone (iPTH) concentration were eligible if they had received a transplant ≥6 months before the study and had an eGFR>30 ml/min per 1.73 m(2) The primary end point was the proportion of patients with normocalcemia at 12 months. Secondary end points were serum iPTH concentration, serum phosphate concentration, bone mineral density, vascular calcification, renal function, patient and graft survival, and economic cost. In total, 30 patients were randomized to receive cinacalcet (n=15) or subtotal parathyroidectomy (n=15). At 12 months, ten of 15 patients in the cinacalcet group and 15 of 15 patients in the parathyroidectomy group (P=0.04) achieved normocalcemia. Normalization of serum phosphate concentration occurred in almost all patients. Subtotal parathyroidectomy induced greater reduction of iPTH and associated with a significant increase in femoral neck bone mineral density; vascular calcification remained unchanged in both groups. The most frequent adverse events were digestive intolerance in the cinacalcet group and hypocalcemia in the parathyroidectomy group. Surgery would be more cost effective than cinacalcet if cinacalcet duration reached 14 months. All patients were alive with a functioning graft at the end of follow-up. In conclusion, subtotal parathyroidectomy was superior to cinacalcet in controlling hypercalcemia in these patients with kidney transplants and persistent hyperparathyroidism.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  calcium; hyperparathyroidism; renal transplantation

Mesh:

Substances:

Year:  2015        PMID: 26647424      PMCID: PMC4978046          DOI: 10.1681/ASN.2015060622

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  35 in total

1.  A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism.

Authors:  P Evenepoel; K Cooper; H Holdaas; P Messa; G Mourad; K Olgaard; B Rutkowski; H Schaefer; H Deng; J V Torregrosa; R P Wuthrich; S Yue
Journal:  Am J Transplant       Date:  2014-09-15       Impact factor: 8.086

2.  Evaluating the safety and rationale for cinacalcet posttransplant hyperparathyroidism and hypercalcemia.

Authors:  D W Coyne; R Delos Santos
Journal:  Am J Transplant       Date:  2014-09-15       Impact factor: 8.086

Review 3.  The surgical management of renal hyperparathyroidism.

Authors:  Catherine Madorin; Randall P Owen; William D Fraser; Phillip K Pellitteri; Brian Radbill; Alessandra Rinaldo; Raja R Seethala; Ashok R Shaha; Carl E Silver; Matthew Y Suh; Barrie Weinstein; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-20       Impact factor: 2.503

Review 4.  Management of mineral and bone disorder after kidney transplantation.

Authors:  Kamyar Kalantar-Zadeh; Miklos Z Molnar; Csaba P Kovesdy; Istvan Mucsi; Suphamai Bunnapradist
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

5.  Cinacalcet attenuates hypercalcemia observed in mice bearing either Rice H-500 Leydig cell or C26-DCT colon tumors.

Authors:  Matthew Colloton; Edward Shatzen; Bernadette Wiemann; Charlie Starnes; Sheila Scully; Charles Henley; David Martin
Journal:  Eur J Pharmacol       Date:  2013-04-23       Impact factor: 4.432

6.  Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism.

Authors:  Hege Pihlstrøm; Dag Olav Dahle; Geir Mjøen; Stefan Pilz; Winfried März; Sadollah Abedini; Ingar Holme; Bengt Fellström; Alan G Jardine; Hallvard Holdaas
Journal:  Transplantation       Date:  2015-02       Impact factor: 4.939

Review 7.  Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.

Authors:  Angela E Ballinger; Suetonia C Palmer; Ionut Nistor; Jonathan C Craig; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-12-09

8.  Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients.

Authors:  Marie Courbebaisse; Eric Thervet; Jean Claude Souberbielle; Julien Zuber; Dominique Eladari; Frank Martinez; Marie-France Mamzer-Bruneel; Pablo Urena; Christophe Legendre; Gerard Friedlander; Dominique Prié
Journal:  Kidney Int       Date:  2008-10-15       Impact factor: 10.612

9.  Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis.

Authors:  Rajeev Narayan; Robert M Perkins; Elizabeth P Berbano; Christina M Yuan; Robert T Neff; Eric S Sawyers; Fred E Yeo; Gwenaelle M Vidal-Trecan; Kevin C Abbott
Journal:  Am J Kidney Dis       Date:  2007-06       Impact factor: 8.860

Review 10.  Management of hypercalcemia after renal transplantation.

Authors:  José-Vicente Torregrosa; Xoana Barros
Journal:  Nefrologia       Date:  2013-11-13       Impact factor: 2.033

View more
  37 in total

1.  Parathyroidectomy or Calcimimetic to Treat Hypercalcemia after Kidney Transplantation?

Authors:  Masafumi Fukagawa; Tilman B Drüeke
Journal:  J Am Soc Nephrol       Date:  2016-01-15       Impact factor: 10.121

2.  Image Diagnosis: Disappearing Digits: Metabolic Bone Disease in End-Stage Renal Disease.

Authors:  Shitij Arora; Fathima Jahufar
Journal:  Perm J       Date:  2019-05-17

3.  Ultrasound-based scores as predictors for nodular hyperplasia in patients with secondary hyperparathyroidism: a prospective validation study.

Authors:  Jill Gwiasda; Alexander Kaltenborn; Jörg A Müller; Michaela Serttas; Georg W F Scheumann; Harald Schrem; Mark D Jäger
Journal:  Langenbecks Arch Surg       Date:  2017-01-04       Impact factor: 3.445

Review 4.  [Management of secondary hyperparathyroidism-current impact of parathyroidectomy].

Authors:  Emanuel Zitt; Karl Lhotta
Journal:  Wien Med Wochenschr       Date:  2016-02-25

5.  Electrolyte Disorders in Kidney Transplantation.

Authors:  Clifford D Miles; Scott Gregory Westphal
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-17       Impact factor: 8.237

Review 6.  Osteoporosis in patients with diabetes after kidney transplantation.

Authors:  Elvira O Gosmanova; Aidar R Gosmanov
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

7.  Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK).

Authors:  T Weber; C Dotzenrath; H Dralle; B Niederle; P Riss; K Holzer; J Kußmann; A Trupka; T Negele; R Kaderli; E Karakas; F Weber; N Rayes; A Zielke; M Hermann; C Wicke; R Ladurner; C Vorländer; J Waldmann; O Heizmann; S Wächter; S Schopf; W Timmermann; D K Bartsch; R Schmidmaier; M Luster; K W Schmid; M Ketteler; C Dierks; P Schabram; T Steinmüller; K Lorenz
Journal:  Langenbecks Arch Surg       Date:  2021-04-21       Impact factor: 3.445

Review 8.  Bone Mineral Disease After Kidney Transplantation.

Authors:  Josep-Vicent Torregrosa; Ana Carina Ferreira; David Cucchiari; Aníbal Ferreira
Journal:  Calcif Tissue Int       Date:  2021-03-25       Impact factor: 4.333

Review 9.  Metabolic Disorders with Kidney Transplant.

Authors:  Elizabeth Cohen; Maria Korah; Glenda Callender; Renata Belfort de Aguiar; Danielle Haakinson
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-13       Impact factor: 8.237

Review 10.  Bone and Mineral Disease in Kidney Transplant Recipients.

Authors:  Pascale Khairallah; Thomas L Nickolas
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.